InMed Pharmaceuticals Inc.
INM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $9 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -37% | 40.9% | 13.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 36% | 44.2% | 13.9% | 41.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -140.2% | -137.1% | -157.8% | -188.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -154.2% | -137.1% | -168.1% | -231.6% |
| EPS Diluted | -436.69 | -1.22 | -2.77 | -5.24 |
| % Growth | -35,694.3% | 56% | 47.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |